Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 5 | 0 | 5 |
| 2000 | 3 | 0 | 3 |
| 2001 | 5 | 1 | 6 |
| 2002 | 4 | 0 | 4 |
| 2003 | 8 | 2 | 10 |
| 2004 | 5 | 1 | 6 |
| 2005 | 3 | 0 | 3 |
| 2006 | 11 | 1 | 12 |
| 2007 | 7 | 0 | 7 |
| 2008 | 9 | 2 | 11 |
| 2009 | 5 | 0 | 5 |
| 2010 | 12 | 0 | 12 |
| 2011 | 4 | 0 | 4 |
| 2012 | 5 | 0 | 5 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 8 | 0 | 8 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 5 | 0 | 5 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 1 | 2 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Immunostaining for polycomb group protein EZH2 as a diagnostic tool to differentiate urothelial carcinoma in situ from benign lesions. Hum Pathol. 2025 Jun; 160:105823.
-
Preoperative CT-based radiomics model for predicting muscle invasion in patients with upper tract urothelial carcinoma below T3 stage. Abdom Radiol (NY). 2025 Dec; 50(12):5872-5882.
-
Appearance of the Upper Urinary System After Treatment. Urol Clin North Am. 2025 Feb; 52(1):139-152.
-
Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis. Urol Oncol. 2024 11; 42(11):361-369.
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 12 10; 41(35):5437-5447.
-
Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma. JCO Precis Oncol. 2023 08; 7:e2300293.
-
Exploring the mechanism of BK polyomavirus-associated nephropathy through consensus gene network approach. PLoS One. 2023; 18(6):e0282534.
-
Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
-
Drug instillation in the management of urinary tract urothelial carcinoma. Curr Opin Urol. 2022 09 01; 32(5):531-535.
-
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):453.e19-453.e26.